Figure 3.

The five drug immunosuppressive regimen lessens humoral and cellular immunity against adenoviral capsid antigens. (a) Follow-up by flow cytometry assessments of the absolute numbers of CD19⁺ B-lymphocytes, CD4⁺ T-cells, and CD8⁺ T-cells in the peripheral blood of the indicated macaques. Arrows point to the dates of AdCMVHSV1-tk injections. (b) Sequential follow-up of serum antiadenoviral neutralizing antibodies in the color-coded animals as described in Figure 2a. (c) Sequential follow-up of the proliferative response of PBMC from the indicated color-coded macaques to adenoviral capsids. (d,e) Proliferation assessed by CFSE dilution in gated (d) CD4⁺ T-cells and (e) CD8⁺ T-cells drawn from the peripheral blood of the indicated color-coded macaques 6 weeks after the second adenoviral infusion. CFSE, carboxyfluorescein succinimidyl ester; nAb, neutralizing antibody.